Objective: To evaluate the profile of the
Brazilianvaginal ring user, reasons for choosing it, satisfaction, menstrual
pattern, tolerability, efficacy, side effects and
reasons for discontinuation. Methods: We reviewed the files of 148 users
who attended the Hospital de Jacarepaguáand private clinics, between 2005 and
2011, in a total of 3107 cycles. Kaplan-Meier survival curves and regression
models were used in statistical analysis. Results: The profile was: single,
nulligravida, 30 years (mean) and with university education. The previous
contraception used was mostly the oral hormonal contraception (75.7%). Women
chose the ring for: practicality (32.4%), forgetting the pill (32.4%) and irregular
vaginal bleeding (13.5%). The satisfaction
degree was 80.5% (119). There were good cycle control and
no pregnancies. Thirty-eight patients discontinued the use (25.7%). The main
reasons were wish for pregnancy (6%),
spotting (3.4%) and increased vaginal discharge (2.7%). At the end of
the first year, use of the greatest reduction of continuity probability was
observed (19.3%). Women with side effects were 68% less likely to be satisfied
with the method than those without (p-value <0.0001). Conclusion: Nuvaring® is an excellent contraceptiveoption due to its sefficacy, cycle control,
tolerability, practicality and safety.
Cite this paper
Monteiro, D. , Bruno, R. , Cabral, Z. , Silva, C. , Barmpas, D. and Rodrigues, N. (2014) Experience of more than 3000 cycles of Brazilian women using the contraceptive vaginal ring (nuvaring®
). Open Journal of Obstetrics and Gynecology
, 10-15. doi: 10.4236/ojog.2014.41003
 Mosher, W.D., Martinez, G.M., Chandra, A., Abma, J.C. and Wilson, S.J. (2004) Use of contraception and use of family planning services in the United States: 1982-2002. Advanced Data, 10, 1-36.
 Trussel, J. (2004) Contraceptive failure in the United States. Contraception, 70, 89-96.
 Melo, N. And Zuccato, A.P. (2004) Satisfaction and non contraceptive benefits with Nuvaring, a novel vaginal combined contraceptive method in a clinical experience program in Brazil. European Journal of Contraception Reproduction Heath Care, 9, 93-98.
 Novak, A., de la Loge, C., Abetz, L. and van der Meulen, E.A. (2003) The combined contraceptive vaginal ring, NuvaRing: An international study of user acceptability. Contraception, 67, 187-194.
 Potter, L., Oakley, D., de León-Wong, E. and Canamar, R. (1996) Measuring compliance among oral contraceptive users. Family Planning Perspectives, 28, 154-158.
 Burkman, R.T. (2001) Oral contraceptives: Current status. Clinical Obstetrics and Gynecology, 44, 62-72.
 Creinim, M.D., Meyn, L.A., Borgatta, L., Barnhart, K., Jensen, J., Burke, A.E., Westhoff, C., Gilliam, M., Dutton, C. and Ballagh, S.A. (2008) Estudo multicêntrico comparando anel e adesivo na contracep??o. Obstetrics & Gynecology, 111, 267-277.
 Food and Drug Administration (Estados Unidos) (2001) “sz” (PDF), 8.
 Bitzer, J. (2012) The vaginal ring (NuvaRing®
) for contraception in adolescent women. Gynecological Endocrinology, 28, 125-129.
 Carey, A.S., Chiappetta, L., Tremont, K., Murray, P.J. and Gold, M.A. (2007) The contraceptive vaginal ring: Female adolescents’ knowledge, attitudes and plans for use. Contraception, 76, 444-450.
 Lete, I., Doval, J.L., Pérez-Campos, E., et al. (2007) Factors affecting women’s selection of a combined hormonal contraceptive method: The TEAM-06 Spanish cross-sectional study. Contraception, 76, 77-83.
 Ahrendt, H.J., Nisand, I., Bastianelli, C., et al. (2006) Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone. Contraception, 74, 451-457.
 Fine, P.M., Tryggestad, J., Meyers, N.J. and Haghpeykar, H.S. (2007) Safety and acceptability with the use of a contraceptive vaginal ring after surgical or medical abortion. Contraception, 75, 367-371.
 Schafer, J.E., Osborne, L.M., Davis, A.R. and Westhoff, C. (2006) Acceptability and satisfaction using quick start with the contraceptive vaginal ring versus an oral contraceptive. Contraception, 73, 488-492.
 Westhoff, C.L., Heartwell, S., Edwards, S., et al. (2007) Oral contraceptive discontinuation: Do side effects matter? American Journal of Obstetrics & Gynecology, 196, 411-417. http://dx.doi.org/10. 1016/j.ajog.2006.12.015
 Roumen, F.J., Apter, D., Mulders, T.M. and Dieben, T.O. (2001) Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyloestradiol. Human Reproduction, 16, 469-475.
 Oddsson, K., Leifels-Fischer, B., Wiel-Masson, D., et al. (2005) Superior cycle control with a contraceptive vaginalring compared with an oral contraceptive containing 30 microgethinylestradiol and 150 microglevonorgestrel: A randomized trial. Human Reproduction, 20, 557-562.
 Roumen, F.J. and Mishell Jr., D.R. (2012) The contraceptive vaginal ring, NuvaRing(®
), a decade after its introduction. European Journal of Contraception Reproduction Heath Care, 17, 415-427.